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Background & Objective. IRIS is an important complication that occurs during management of HIV-TB coinfection and it poses
difficulty in diagnosis. Previous studies have reported variable incidence of IRIS. The present study was undertaken to describe
the pattern of TB-associated IRIS using recently proposed consensus case-definitions for TB-IRIS for its use in resource-limited
settings. Methods. A prospective analysis of ART-naı¨ve adults started on HAART from November, 2008 to May, 2010 was done in a
tertiary care hospital in north India. A total 224 patients divided into two groups, one with HIV-TB and the other with HIV alone,
were followedup for a minimum period of 3 months. The diagnosis of TB was categorised as “definitive” and “probable”. Results.
Out of a total of 224 patients, 203 completed followup. Paradoxical TB-IRIS occurred in 5 of 123 (4%) HIV-TB patients while 6
of 80 (7.5%) HIV patients developed ART-associated TB. A reduction in plasma viral load was significantly (P = .016) associated
with paradoxical TB-IRIS. No identifiable risk factors were associated with the development of ART-associated TB. Conclusion.
The consensus case-definitions are useful tools in the diagnosis of TB-associated IRIS. High index of clinical suspicion is required
for an early diagnosis.
1. Introduction
Human immunodeficiency virus/acquired immunodefi-
ciency syndrome (HIV/AIDS) and tuberculosis (TB) are
leading causes of morbidity and mortality worldwide [1].
The incidence of TB is highest among patients with advanced
HIV disease [2]. A majority of the global burden of
HIV-associated TB lies in resource-constrained countries
[1]. Antiretroviral treatment (ART) has been made widely
available in these areas over last several years now. However,
many patients in these countries start ART at a late stage
when they have advanced HIV/AIDS [3]. The beneficial
effects of ART result from gradual restoration of pathogen-
specific immune responses mediated by suppressed HIV-1
replication and increased CD4 cell count [4]. The fact that
many patients accessing ART are already receiving treatment
for TB presents a major clinical challenge due to the com-
plexities involved in the concurrent management of these
two coinfections [5–8]. In addition to high pill burden, drug
cotoxicity and pharmacokinetic drug interactions, “immune
reconstitution inflammatory syndrome” (IRIS) also called
“immune reconstitution syndrome” (IRS) has been a major
problem. The syndrome is usually a consequence of exag-
gerated activation of the immune system against persistent
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antigen (paradoxical IRIS) or viable pathogens (unmasking
IRIS), but it can also develop as progression of prolif-
erative disease in patients with cancers [9]. IRS is asso-
ciated with certain infectious (e.g., mycobacteria, varicella
zoster, cytomegalovirus) and noninfectious (autoimmune or
neoplastic) conditions. ART-induced IRS includes either a
paradoxical worsening of treated opportunistic infections
(paradoxical form) or the unmasking of previously subclin-
ical, untreated infections (unmasking form) [10–12]. TB-
associated IRIS has been reported in up to 43% of patients
receiving concurrent treatment for these infections [13–28].
In an earlier publication where consensus case-definitions
were applied retrospectively, 18 (7.5%) of 237 patients with
TB at baseline had paradoxical TB-associated IRIS [29].
There has so far been only one [27] prospective study on
TB-IRIS in India and most of the studies worldwide are also
retrospective. In this communication, we report findings of
a prospective study in HIV/AIDS patients started on highly
active antiretroviral treatments (HAART) who were followed
up at least for a predefined period for development of IRIS;
TB-associated IRIS being of major interest.
2. Materials and Methods
We report findings of a prospective, observational study
between November, 2008 to May, 2010 to determine the
incidence of IRIS in patients with HIV-associated TB
and to identify the risk factors for TB-IRIS. The study
included adult HIV/AIDS patients who attended the out-
patient department, ART clinic or were admitted to the
All India Institute of Medical Sciences Hospital (AIIMS,
New Delhi, India). The ART centre was opened at AIIMS
hospital in May 2005 as part of National AIDS Control
Programme started in April 2004. The hospital provides
tertiary care to the population of Delhi and its neigh-
bouring states and most of its patients come from the
lower socioeconomic strata. The hospital and the clinic
provides service to both newly diagnosed as well as referred
cases.
Following were exclusion criteria: development of hyper-
sensitivity to antiretroviral or antituberculosis drugs, past
history of HAART, pregnancy, anticipated difficulty in
followup and failure to give written informed consent.
Two hundred and twenty four HIV-infected ART-naı¨ve
adults who were recently diagnosed and started on HAART
were divided into two groups: (i) HIV/AIDS patients with
active TB and (ii) HIV/AIDS patients with no evidence of
active TB at the time of recruitment in the study. HIV
infection was documented by a licensed third generation
ELISA kit as described in earlier study [30]. Tuberculosis was
diagnosed as described in the previous study [31]. Culture
and drug susceptibility testing (DST) for Mycobacterium
tuberculosis were done in all cases where specimens were
available to rule out drug-resistant TB. TB cases were divided
into two categories—(i) definitive—where Mycobacterium
tuberculosis was demonstrated in smear (Ziehl Neelsen
method) and/or culture (Lowenstein Jensen) or Mycobac-
terium tuberculosis-polymerase chain reaction (Mtb-PCR)
was positive in various body fluids (sputum, bronchoalveolar
lavage fluid, pleural fluid, ascitic fluid, pericardial fluid,
cerebrospinal fluid, bone marrow aspirate, pus specimens
from cold abscesses) and (ii) probable—where specimen for
smear and/or culture or Mtb-PCR was negative or could not
be obtained due to technical difficulties. Criteria for diag-
nosis included: (a) pulmonary infiltrates located at classical
site with no response to antibiotics; (b) exudative effusion
or other body fluids with predominantly lymphocytes and
elevated adenosine deaminase (ADA) activity (>35U/L);
(c) imaging (chest radiograph, ultrasonography, computed
tomography and magnetic resonance imaging) highly sug-
gestive of TB especially intrathoracic and abdominal lymph
nodes with central hypodensity and peripheral rim enhance-
ment; (d) imaging showing lesions in liver, spleen, intestine,
bone and brain highly suggestive of TB (image-guided aspi-
ration from lymph nodes or other lesions not possible due to
technical difficulty); (e) clinical and radiological response to
antiTB treatment during followup. Any one of criteria (a) to
(d) along with (e) was required to be present for the diagnosis
of probable TB. Both definitive and probable TB cases were
included. The Institutional Ethics Committee approved the
study. Written informed consent was obtained from all
patients.
Patients underwent a thorough clinical examination on
enrolment and subsequently every month as they came to the
ART clinic for followup and collection of antiretroviral drugs
in accordance with the Guidelines of National AIDS Control
Organisation (NACO) ofMinistry of Health and FamilyWel-
fare, Government of India [32, 33]. All details were recorded
in a predesigned proforma. Patients with TB were provided
treatment free of cost from Directly Observed Treatment
Short-Course (DOTS) centre in accordance with the Revised
National Treatment Control Programme (RNTCP) of Min-
istry of Health and Family Welfare, Govt. of India [34,
35]. Anti-TB treatment was administered intermittently,
thrice a week while the ART was administered daily as
described earlier [34, 35]. The time of HAART initiation was
decided as per NACO guidelines [32]. Medical social workers
ensured regular visits of the patients to the DOTS and ART
clinics.
The minimum followup period was 3 months for
development of IRIS. All the patients were followed up
till the end of the study. Hence those who were recruited
earlier would have had longer followup than those who
were recruited later. Patients were contacted telephonically
or their houses were visited in case they failed to turn
up for their scheduled visits [33, 35]. End point of the
study was development of TB-IRIS according to the case-
definitions. Diagnosis of IRIS was based on published case-
definitions criteria published by Meintjes et al. [36] for TB-
associated IRIS and French et al. [37] for other cases. In
cases where IRIS developed, change in CD4 count, plasma
viral load, haematological and biochemical parameters were
noted. CD4 count and HIV viral load were estimated using
flow-cytometry (Becton Dickinson, USA) and Amplicor
HIV-1 Monitor Test (Reverse Transcriptase Polymerase
Chain Reaction, Roche Diagnostics Corp., Indianapolis),
respectively.
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Table 1: Baseline characteristics of 203 patients with HIV/AIDS.
HIV-TB (n = 123) HIV (n = 80)
Age (yrs) 36 ± 10 35 ± 9
Sex (% male) 80∗ 59∗
BMI (kg/m2) 19 ± 4.5 19.6 ± 3.8
CD4 (cells/μl) 137 (72–222)† 198 (93–238)†
Plasma VL (log10 copies/ml) 5.23 (4.79–5.65) 5.09 (4.55–5.65)
BMI: body mass index; VL: viral load
Age and BMI are presented as mean± SD; gender as % of male and CD4 cell
counts and viral load as median and IQR
∗P = .001
†P = .038.
2.1. Statistical Analysis. Continuous data are presented as
mean ± standard deviation (for normally distributed vari-
ables) or median and interquartile range or IQR (for variable
influenced by extreme values). Categorical data are presented
as numbers with proportions, n(%). Percentage reduction in
viral load has been calculated by dividing absolute reduction
in viral load by baseline viral load and then multiplying it by
100. The categorical data were compared between groups by
the Chi square or Fisher’s exact test and continuous variables
by the Mann-Whitney U-test. All tests were two-sided, and
P < .05 was considered statistically significant. All analyses
were using a statistical software package (Intercooled Stata
8.0 for Windows, Stata Corporation, College Station, TX,
USA).
3. Results
Study data are summarized in Figure 1. As per case-
definitions, all patients were followed-up for a minimum
period of 3 months. A total of 203 patients (123 in HIV-
TB group and 80 patients in HIV group) has completed
3 months followup and TB-IRIS data of these patients are
being reported.
Pretreatment absolute CD4 count was significantly lower
in HIV-TB group (137 (IQR 72–222) versus 198 (IQR 93–
238) cells/μl, P = .038) compared to HIV group (Table 1).
HIV-TB group had 123 patients; 98 (80%) had extrapul-
monary TB (EPTB) (39 (32%) of these had disseminated TB)
while 25 (20%) patients had pulmonary TB (PTB) (Table 2).
Forty eight of 123 (39%) patients had “definitive” TB
and remaining 75 patients had “probable” TB. Of these
75 probable TB cases, all had imaging features compatible
with TB, 38 of 75 patients had cytological and biochemical
characteristics in body fluids (pleural effusion, ascites or
CSF), 3 had histopathological findings highly suggestive of
TB and all of them showed clinical and imaging response
to antiTB treatment during followup (minimal followup 3
months in the last recruited patients). A detailed description
has been provided in Tables 3a and 3b.
In total, 5 (4%) of 123 patients with TB at baseline started
on HAART had paradoxical TB-associated IRIS (Table 4),
while 6 (7.5%) of 80 patients without TB at baseline
developed ART-associated TB after starting HAART. All 11
episodes of IRIS and ART-associated TB occurred within
Table 2: Detailed description of 123 TB patients in the HIV-TB
group.
Type/site of TB HIV-TB group
PTB [n(%)] 25 (20)∗
EPTB [n(%)] 98 (80)
DTB [n(%)] 39 (32)
Lung + Pleura + mediastinal LN [n(%)] 11 (9)∗
Pleura + RP/mesenteric LN [n(%)] 6 (5)
Lung + pleura [n(%)] 4 (3)
Ascites + RP/mesenteric LN + mediastinal
LN [n(%)]
4 (3)
Ascites + hepatosplenomegaly +
RP/mesenteric LN + mediastinal LN
[n(%)]
3 (2)
Lung + pleura + Ascites + RP/mesenteric
LN [n(%)]
3 (2)
Ascites + hepatosplenomegaly +
mediastinal LN [n(%)]
2 (2)
Lung + pleura + Ascites +
hepatosplenomegaly + RP/mesenteric LN
[n(%)]
2 (2)
Lung + pleura + Ileocaecal +
RP/mesenteric LN [n(%)]
2 (2)
Cervical LN + mediastinal LN +
RP/mesenteric LN [n(%)]
2 (2)
Abdomen [n(%)] 23 (19)
Ascites + RP/mesenteric LN [n(%)] 8 (7)
Ascites + hepatosplenomegaly +
RP/mesenteric LN [n(%)]
7 (6)
Ascites + hepatosplenomegaly [n(%)] 4 (3)
Ileocaecal + RP/mesenteric LN [n(%)] 4 (3)
Lymph node [n(%)] 16 (13)
Cervical [n(%)] 10 (8)†
Abdominal [n(%)] 4 (3)
RP + mesenteric LN 2 (2)
RP LN 1 (1)
Periportal + mesenteric LN 1 (1)
Mediastinal [n(%)] 2 (2)
Pleural effusion [n(%)] 11 (9)
CNS [n(%)] 6 (5)
Meningitis [n(%)] 3 (2)
Tuberculoma [n(%)] 2 (2)
Meningitis + Tuberculoma [n(%)] 1 (1)
MTB [n(%)] 2 (2)
Pott’s spine [n(%)] 1 (1)
PTB: pulmonary tuberculosis; EPTB: extra pulmonary tuberculosis; RP:
retroperitoneal; LN: lymph nodes; CNS: central nervous system; DTB:
disseminated tuberculosis; MTB: military tuberculosis
EPTB is presented as % of TB; Types of EPTB as % of EPTB; Subtypes of
EPTB types as % of EPTB along with absolute no. of cases
∗One patient each from these groups developed paradoxical TB-IRIS
†Three patients from this group developed paradoxical TB-IRIS.
3 months of starting HAART. Median intervals between
initiation of HAART and occurrence of paradoxical TB-IRIS
4 Clinical and Developmental Immunology
224 patients with HIV
134 with HIV and TB 90 with HIV but no active TB
7 died 2 died
2 transferred out
5 developed paradoxical
TB-IRIS
6 developed ART-
associated TB
1 PMLE
1 HZ
1 CMV
1 Crypto
1 CMV
1 HZ
123 completed 3 months follow-up 80 completed 3 months follow-up
4 lost to follow-up 6 lost to follow-up
4 developed nonTB-IRIS 2 developed nonTB-IRIS
Figure 1: Study profile. HIV: human immunodeficiency virus; TB: tuberculosis; IRIS: immune reconstitution inflammatory syndrome;
PMLE: progressive multifocal leukoencephalopathy; HZ: herpes zoster; CMV: cytomegalovirus; Crypto: cryptococcal meningitis.
and ART-associated TB were 73 (IQR 6–84) and 37 (IQR 7–
88) days, respectively. Comparisons of clinical characteristics
of different groups of patients have been detailed in Tables 5,
6 and 7. None of these patients died during followup period.
Most common clinical manifestation in patients with
paradoxical worsening was new onset fever, anorexia and
weight loss. A detailed description has been provided in
Table 8. All had definitive TB (Table 9) and multidrug-
resistant TB was ruled out by DST. All episodes were of
mild to moderate severity not requiring any interruption
of HAART. Hospitalization was required in 3 of 5 patients.
Two patients required repeated aspiration of TB cervical cold
abscesses. Symptoms of paradoxical deterioration resolved
within one week with continued treatment, antipyretics
(paracetamol), analgesics (nonsteroidal antiinflammatory
drugs) and none required steroids.
In 6 patients with ART-associated TB, 5 had pulmonary
TB and 1 had TB lymphadenitis—diagnosis of TB was
definitive in all cases (Tables 8, 9). None of these patients
had an inflammatory clinical presentation, for example, TB
lymphadenitis or abscesses with prominent acute inflam-
matory features or pulmonary tuberculosis complicated by
respiratory failure due to adult respiratory distress syn-
drome, suggestive of unmasking TB-associated IRIS. None
of these patients required hospitalization. All patients were
administered antiTB treatment and showed good response
to treatment.
There were total 6 (2.7%) cases of nonTB-IRIS—2
patients with herpes zoster, 2 patients with cytomegalovirus
infection (IgM positive and biopsy from gut lesion showing
characteristic cytopathic effect), 1 patient with cryptococcal
meningitis (India ink and cryptococcal antigen in CSF
positive) and 1 patient with progressive multifocal leukoen-
cephalopathy (confirmatory findings on MRI brain and
culture for JC virus positive).
On univariate analyses, age, gender, body mass index,
presence of extra-pulmonary/disseminated TB, baseline CD4
count, percentage change in CD4 and baseline viral load
were not significantly associated with the development of
paradoxical TB-associated IRIS or ART-associated TB. In
patients who developed paradoxical TB-associated IRIS, the
median interval between the initiation of antiTB treatment
and HAART was shorter as compared to those who did
not develop although the difference was not statistically
significant (20 (IQR 18–27) versus 32 (IQR 21–70) days;
P = .136). There was a significantly higher reduction in
viral load (99.93 (IQR 99.91–99.97) versus 99.58 (IQR 98.85–
99.9) %; P = .016) in patients who developed paradoxical
TB-associated IRIS (Table 5). The similar trend was found in
patients with ART-associated TB but it was not statistically
significant (Table 6). However, when patients with any IRIS
and ART-associated TB were compared with those who did
not develop IRIS, statistically significant differences were
found in increase in CD4 (136 (IQR 60–272) versus 53 (IQR
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Table 3: (a) Method of “definitive∗” TB diagnosis in HIV-TB
group. ∗Mycobacterium tuberculosis demonstrated in smear and/or
culture and/or TB—polymerase chain reaction (PCR) positive in
body fluids. PCR: polymerase chain reaction; BAL: bronchoalveolar
lavage; CSF: cerebrospinal fluid; LN: lymph node. †In 25 cases fine
needle aspiration was done, 12 of these showed Mycobacterium
tuberculosis. ‡One patient from this group developed paradoxical
TB-IRIS. §One patient from this group developed paradoxical
TB-IRIS. (b) Method of “probable∗” TB diagnosis in HIV-TB
group. ∗Specimens for smear or culture or PCR for Mycobacterium
tuberculosis negative or could not be obtained. †High resolution
or contrast-enhanced computed tomography (CECT) of chest
showing—centrilobular nodules with tree-in-bud appearance, mil-
iary nodules, thick walled cavities, enlarged mediastinal lymph
nodes with central hypodensities and peripheral rim enhancement
suggestive of necrosis; CECT of abdomen showing enlarged liver
or spleen with multiple hypodensities suggestive of granulomas
or abscesses, matted bowel loops, thickening of terminal ileum
and caecum, enlarged necrotic mesenteric or retroperitoneal lymph
nodes; CECT and/or magnetic resonance imaging (MRI) of
brain showing basal meningitis and/or multiple ring enhancing
lesion suggestive of tuberculomas; MRI of spine showing loss of
intervertebral space with destruction of vertebral bodies with or
without paravertebral abscesses. ‡Elevated protein, predominantly
lymphocytes and high adenosine deaminase level. §FNAC or biopsy
showing granulomas with caseation necrosis. ¶,‖,∗∗One patient each
from these groups developed paradoxical TB-IRIS.
(a)
Specimen type
Test (positive/performed)
Smear Culture TB-PCR Overall
Sputum 12‡/25 — — 12
BAL 0/4 2/4 — 2
Pleural fluid 0/39 0/39 9/39 9
Ascitic fluid 0/28 0/28 6/28 6
CSF 0/6 2/6 3/6 3
Bone marrow aspirate 0/2 2/2 2/2 2
LN aspirate 14§/27† 2/2 2/2 14
Total 48
(b)
Characteristic findings No. present
(i) Radiological† 75¶,‖,∗∗
(ii) Body fluids‡ 39
Pleural effusion 22¶
Ascites 14
CSF 3
(iii) Histopathological§ 3‖
(i) + (ii) + (iii) 1
(i) + (ii) 38¶
(i) + (iii) 2‖
(i) 34∗∗
Total 75
15–146) %; P = .023) and decrease in viral load (99.91 (IQR
99.8–99.93) versus 99.55 (IQR 98.76–99.9) %; P = .002).
4. Discussion
In present study 4% of patients with HIV-associated TB
developed paradoxical TB-associated IRIS after starting
HAART and 7.5% of patients with no overt evidence of
TB at initiation of HAART developed ART-associated TB.
Only a few prospective studies have been published using
the consensus case-definitions for TB-IRIS. Earlier studies
from developed nations had reported a high incidence of
TB-associated IRIS (17–43%) as compared to studies from
developing nations (2–13%) [13–28]. Kumarasamy et al.
[27] from southern India in their recent publication found
the incidence of paradoxical TB-associated IRIS to be 5.5%.
The results of present study are similar to a recent pub-
lication from our centre where authors applied consensus
case-definitions criteria retrospectively [29] and in this study
also no case of ART-associated TB fulfilling the criteria
of unmasking TB-IRIS was reported. Incidence rates of
paradoxical TB-IRIS and ART-associated TB were 7.5% and
3%, respectively in that study. Authors observed significant
differences in baseline CD4 count and change in the CD4
cell count after 6 months between patients who developed
paradoxical TB-IRIS and those who did not.
The higher incidence of TB-IRIS reported, particularly in
the western literature, can be explained by leniency of clinical
diagnostic criteria. Moreover, clinical diagnosis is readily
made by the experts working in the field of HIV-TB. Hence,
the staff of ART clinics should be adequately trained to
suspect, categorise and confirm the diagnosis by appropriate
investigations. Institutional adjudication committee may
look into the diagnosis of IRIS. There should also be a
proper reporting system to the higher agencies which could
be further facilitated by establishing regional or national
registry. An effort from the NACO in this regard will be
highly welcome. The true incidence of TB-IRIS may be
known from future studies with the application of consensus
case definitions.
The lack of application of uniform case-definitions for
TB-associated IRIS across various published studies makes
direct comparison of these results difficult. Recently, an
International Network for the Study of HIV-associated
IRIS (INSHI) case-definitions for TB-associated IRIS has
been proposed for their use in resource-limited settings
[36]. These have been validated in both retrospective and
prospective studies [38, 39] and have shown good agreement
with other published case definitions and expert opinions for
IRIS. In the present study we have used these proposed case-
definitions for the diagnosis of TB-associated IRIS.
Though the consensus case-definitions can be easily
applied in resource-limited settings where it is not always
possible to get CD4 count or plasma viral load readily and
regularly, it seems to have some limitations. First, it would
have missed the patients who developed paradoxical TB-
associated IRIS after 90 days of HAART—while it is still
a possibility, even keeping in mind the chance of a new
infection. Second, the definition for unmasking TB-IRIS
seems to be too stringent to be applicable in clinical practice
and the arbitrary cut-off of 3 months is likely to miss a few
cases.
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Table 4: Diagnosis of paradoxical TB-IRIS according to consensus case-definition.
Sl. no.
TB
TB-IRIS
Clinical criteria∗
Site Category Major Minor
(1)
DTB (Lung + Pleura
+ mediastinal LN)
Probable
DTB (Lung + Pleura +
mediastinal +
RP/mesenteric LN)
New LN
Worsening constitutional
symptoms (fever, weight loss, etc.)
(2) LNTB (cervical) Definitive
DTB (cervical +
mediastinal +
RP/mesenteric LN)
New LN
Worsening constitutional
symptoms
(3) LNTB (cervical) Probable
DTB (cervical +
mediastinal +
RP/mesenteric LN)
New LN
Worsening constitutional
symptoms
(4) PTB Definitive PTB Worsening CXR
Worsening constitutional
symptoms
Worsening respiratory symptoms
(cough, dyspnoea, etc.)
(5) LNTB (cervical) Probable LNTB (cervical)
New &
enlarging LN
Worsening constitutional
symptoms
PTB: pulmonary tuberculosis; RP: retroperitoneal; LN: lymph nodes; DTB: disseminated tuberculosis
∗“Antecedent requirements” and “Alternative explanations for clinical deterioration” criteria were fulfilled in all the cases.
Table 5: Comparison characteristics between patients with and
without TB-IRIS in 123 patients with HIV-TB.
No. TB-IRIS TB-IRIS
(n = 118) (n = 5)
Age (yrs) 37 ± 10 31 ± 7
Sex (% male) 80 80
BMI (kg/m2) 19 ± 5 18 ± 3
ATT-ART (days) 32 (21–70) 20 (18–27)
CD4 (cells/μl) 136 (70–225.75) 167 (118–193)
Increase in CD4
89 (32.25–144.75) 229 (61–283)
(cells/μl)
Increase in CD4 (%) 57.6 (24–181) 119 (63.5–207)
VL (log10 copies/ml) 5.21 (4.76–5.65) 5.49 (5.18–5.63)
Decrease in VL
5.19 (4.76–5.63) 5.49 (5.18–5.63)
(log10 copies/ml)
Decrease in VL (%) 99.58 (98.85–99.9)∗ 99.93 (99.91–99.97)∗
BMI: body mass index; ATT: antituberculosis treatment; ART: antiretroviral
treatment; VL: viral load
Age and BMI are presented as mean ± SD; gender as % of male; EPTB as %
of TB; DTB as % of EPTB and ATT-ART gap, CD4 cell counts and viral load
as median and IQR
∗P = .016.
Though none of ART-associated TB met the criteria
of heightened inflammatory response to be categorised
as unmasking TB-IRIS in both studies from our centre,
clinicians should remain highly vigilant in HIV patients who
develop TB after starting ART, as they can have much more
severe disease and can deteriorate rapidly due to immune
reconstitution and may even require hospitalization.
In the present study no statistically significant influence
of age, gender, BMI, baseline CD4 or viral load and
magnitude of change in CD4 were found on occurrence
of TB-IRIS as opposed to the findings of previous studies
Table 6: Comparison of characteristics between patients with and
without ART-associated TB in 80 patients with HIV.
No TB ART-associated TB
(n = 74) (n = 6)
Age (yrs) 35 ± 9 35 ± 15
Sex (% male) 60 50
BMI (kg/m2) 19.7 ±3.8 19.4 ± 4
CD4 (cells/μl) 200 (94.25–242) 132 (57.25–182.75)
Increase in CD4
88 (27.25–149.75) 161 (129–316)
(cells/μl)
Increase in CD4 (%) 46 (11.5–126.5) 160 (72–369)
VL (log10 copies/ml) 5.09 (4.54–5.65) 5.28 (4.95–5.51)
Decrease in VL
5.08 (4.5–5.57) 5.13 (4.87–5.39)
(log10 copies/ml)
Decrease in VL (%) 99.58 (98.79–99.9) 99.91 (99.84–99.93)
BMI: body mass index; VL: viral load
Age and BMI are presented as mean± SD; gender as % of male and CD4 cell
counts and viral load as median and IQR
There was no statistically significant difference.
[13–28]. Early initiation of HAART after antiTB treatment
was associated with paradoxical TB-associated IRIS though
not statistically significant as mentioned in previous studies
[13–28]. But decrease in viral load was associated with
paradoxical TB-IRIS as proposed in the literature [4–8].
Extra-pulmonary and disseminated TB has been reported to
be associated with the occurrence of TB-associated IRIS in
previous studies. Though in our study 4 out of 5 paradoxical
reactions occurred in patients with extra-pulmonary TB and
only 1 of those had disseminated TB. These discrepancies
could possibly be due to the small number of IRIS events
in the present study. Though the patients were explained
thoroughly about the possible symptoms of IRIS and strictly
instructed to visit the clinic or contact the investigator on
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Table 7: Comparison of characteristics between HIV-TB patients without and with TB-IRIS and HIV patients with ART associated TB.
No TB-IRIS TB-IRIS ART-associated TB
(n = 118) (n = 5) (n = 6)
Age (yrs) 37 ± 10 31 ± 7 35 ± 15
Sex (% male) 80 80 50
BMI (kg/m2) 19 ± 5 18 ± 3 19.4 ± 4
ATT-ART (days) 32 (21–70) 20 (18–27) —
ART-IRIS (days) — 73 (6–84) 37 (7–88)
CD4 (cells/μl) 136 (70–225.75) 167 (118–193) 132 (57.25–182.75)
Increase in CD4 (cells/μl) 89 (32.25–144.75) 229 (61–283) 161 (129–316)
Increase in CD4 (%) 57.6 (24–181) 119 (63.5–207) 160 (72–369)
VL (log10 copies/ml) 5.21 (4.76–5.65) 5.49 (5.18–5.63) 5.28 (4.95–5.51)
Decrease in VL (log10 copies/ml) 5.19 (4.76–5.63) 5.49 (5.18–5.63) 5.13 (4.87–5.39)
Decrease in VL (%) 99.58 (98.85–99.9) 99.93 (99.91–99.97) 99.91 (99.84–99.93)
BMI: body mass index; ATT: antituberculosis treatment; ART: antiretroviral treatment; VL: viral load
Age and BMI are presented as mean ± SD; gender as % of male and ATT-ART gap, ART-IRIS gap, CD4 cell counts and viral load as median and IQR.
Table 8: Description of TB in patients with TB-IRIS (at the time of
IRIS) and ART-associated TB.
Paradoxical
TB-IRIS (n = 5)∗
ART-associated TB
(n = 6)
PTB [n (%)] 1 5
EPTB [n (%)] 4 1
DTB [n (%)] 3 —
Lung + Pleura +
mediastinal LN +
RP/mesenteric LN [n (%)]
1 —
Cervical LN + mediastinal
LN + RP/mesenteric LN
[n (%)]
2 —
Lymph node [n (%)] 1 1
Cervical [n (%)] 1 1
PTB: pulmonary tuberculosis; EPTB: extrapulmonary tuberculosis; DTB:
disseminated tuberculosis; LN: lymph node
EPTB, types of EPTB and subtypes of EPTB types presented in absolute no.
of cases
∗Three of the 5 patients with paradoxical IRIS had cervical TB lym-
phadenopathy at presentation while one had disseminated and the other
had pulmonary TB. After being started on ART, one with cervical TB
lymphadenopathy developed enlargement of the previously existing lymph
nodes along with appearance of new nodes in the neck; other two with
cervical TB lymphadenopathy developed disseminated TB; in one with
disseminated TB (lung, pleura and mediastinum) the disease became more
extensive (with abdominal involvement); and one with pulmonary TB
developed new chest infiltrates with increased bacillary load in the sputum.
occurrence of any symptoms suspicious of IRIS, monthly
followup schedule might have missed a few cases of IRIS
occurring in between. Another possible explanation for low
incidence of IRIS could be the use of intermittent thrice
weekly antiTB treatment in place of daily drug regimen.
In view of relatively low incidence of TB-IRIS in South-
East Asia, the small sample size of the present study makes it
very difficult to identify the risk factors associated with it.
Extrapulmonary TB which is much more common in
advanced cases of HIV/AIDS has a very low bacillary load in
Table 9: Method of TB diagnosis in patients with TB-IRIS (at the
time of IRIS) and ART-associated TB.
Specimen type
Test (positive/performed)
Smear Culture TB-PCR Overall
TB-IRIS
Sputum 1/1 1/1 — 1
LN aspirate 4/4 4/4 4/4 4
Total 5
ART-associated TB
Sputum 4/5 5/5 — 5
LN aspirate∗ 1/1 — — 1
Total 6
PCR: polymerase chain reaction; LN: lymph node
∗Fine needle aspiration was done in this case and the specimen also showed
necrotizing granulomas on histopathological examination.
samples and it is sometimes not possible to get specimens for
microbiological or histopathological diagnosis due to diffi-
culties with imaging guided procedures [40, 41]. Moreover,
in the developing nations with resource-limited settings,
as opposed to the present study which was conducted in
a tertiary care centre, state-of-the-art imaging for both
diagnosis and followup and other diagnostic facilities (like
ADA level estimation, PCR) are not available in peripheral
centres. The same holds true for diagnosis of other oppor-
tunistic infections particularly viral, fungal and protozoal
infestations. Availability of limited laboratory facilities in
the public hospitals, use of commercial laboratories by the
patients and a lack of accreditation and quality assurance
of these laboratories are real problems. However, it is to be
emphasized here that these definitions have been formulated
for use in the resource-limited settings like ours where access
to such investigations is expected to be limited.
We did not encounter any death due to IRIS. But it will be
prudent to keep in mind that IRIS affecting central nervous
system or producing acute respiratory distress syndrome can
be lethal if not diagnosed timely and treated appropriately.
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Since, till date no single clinical factor has been identified
which can predict development of IRIS, a high index of
clinical suspicion is still the key for an early diagnosis of IRIS.
Further research is needed to better understand the immune-
pathogenesis of the various types of IRIS so that better
diagnostic tests and effective therapies can be developed.
5. Conclusion
TB-associated IRIS reactions are important and may com-
plicate management of HIV-TB coinfection. They should
be promptly recognised and treated. Most cases of TB-
associated IRIS can be managed easily and do not need
discontinuation of ART. The consensus case-definitions seem
to be a useful tool in the diagnosis of TB-associated IRIS in
resource-poor countries where access to laboratory facilities
is limited.
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